Evidence map›Paper›PMID 41362960›Full record

ArticleJournal of surgical oncology2026

Treatment and Outcomes for Patients With Inadequate Lymphadenectomy After Resection of Stage II Small Bowel Adenocarcinoma.

Jackson A Baril, Karl Y Bilimoria, Eugene P Ceppa, Michael G House, Thomas K Maatman, Alexandra M Roch, Anthony D Yang, C Max Schmidt, Ryan J Ellis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jackson A BarilSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Karl Y BilimoriaSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Eugene P CeppaDepartment of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Michael G HouseDepartment of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Thomas K MaatmanDepartment of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Alexandra M RochDepartment of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Anthony D YangSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
C Max SchmidtDepartment of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Ryan J EllisSurgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Funding

Surgical Oncology Research Training at Indiana (SORTI)T32CA282070 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI KARL Y BILIMORIA, Harikrishna Nakshatri · 2024 to 2026
$1.5M
Funder National Cancer Institute of the National Institutes of Health (Grant T32CA282070).NCI NIH HHS T32 CA282070
6 · The paper itself

Abstract

BACKGROUND AND

objectivesAdjuvant chemotherapy (AC) is considered for patients with stage II small bowel adenocarcinoma (SBA) with an inadequate lymphadenectomy; however, the prognostic role of additional high-risk features (T4 primary, positive resection margin, poorly differentiated tumor, or lymphovascular invasion) is unknown. The objectives were to describe utilization of AC among patients with stage II SBA with inadequate lymphadenectomy, identify factors associated with receipt of AC, and examine the association between AC and survival stratified by presence of additional high-risk features.

methodsPatients with stage II SBA were identified using the National Cancer Database from 2004 to 2021. Inadequate lymphadenectomy was defined < 5 lymph nodes duodenal tumors and < 8 lymph nodes other sites.

resultsOf 1765 patients with stage II SBA and an inadequate lymphadenectomy, 525 (29.8%) received AC. T4 primary, poor grade tumor, and positive resection margin were associated with receiving AC. Receipt of AC was associated with improved 5-year survival in patients with additional high-risk features (49.9% vs 31.4%; HR 0.62, 95%CI 0.48-0.79) but not in patients without additional high-risk features (67.1% vs. 53.2%; HR 0.83, 95%CI 0.55-1.24).

conclusionsReceipt of AC was associated with improved survival in patients with inadequate lymphadenectomy and any additional high-risk feature. Multiple variables may be considered in decisions regarding AC.

Indexed as

AdenocarcinomaIntestinal NeoplasmsIntestine, SmallLymph Node ExcisionAdultAgedChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesSurvival Rateadjuvant chemotherapyIntestinal NeoplasmslymphadenectomyRetrospective Studysmall Intestine/surgery

Identifiers

PMID41362960
PMCPMC12863234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.